 8. Patients must not require ongoing therapy with non-steroidal anti-inflammatories NSAIDs,other than low-dose i.e. 81 mg or less aspirin daily, i.v. vancomycin, aminoglycosides, or other potently nephrotoxic drugs, and must agree to abstain from NSAIDs for the duration of their participation in the trial 